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A human monoclonal macroglobulin IgM"°", has recently been described which
has specificity for poly-a(2-"8)-linked N-acetylneuraminic acid (NeuNAc), 1 the
specific capsular polysaccharide of the group B meningococcus and of Escherichia
coli Kl (1). Although studies using this polysaccharide as a vaccine in humans have
been unsuccessful (2-4, see reference 5), the serum contained over 20 mg of anti-
body per milliliter. Quantitative precipitin curves of IgM"°" with four preparations,
two of group B meningococcal polysaccharide and two ofE. coli Kl were identical
(1). IgM"°" did not precipitate with polysaccharides from group C meningococci
composed of poly-a(2-9)NeuNAc nor with E. coli K92 built of alternating
a(2-8)a(2-9)NeuNAc, nor with many other polysaccharides. 2 Surprisingly, the
polynucleotides poly(A) and poly(I) gave precipitin curves per unit weight identical
with those of poly-a(2-8)NeuNAc. Denatured DNA and poly(G) also crossreacted,
but about 3 and 12 times as much, respectively, was needed to precipitate comparable
amounts of antibody nitrogen (N) from IgM"°"(1). These crossreactivities would ap-
pear to correspond to the findings of Heidelberger (6) who interpreted the extensive
crossreaction between types 8 and 19 pneumococcal polysaccharides as due to the
negatively charged phosphoryl-Q-D-ManNAc oftype 19 being able to enter the type
8 antibody combining site which is specific for cellobiuronic acid with its carboxyl
and vice versa. It was postulated (1) therefore, that the crossreactions with poly(A),
poly(I) and denatured DNA could be accounted for by "a similarity in the spatial
distribution of charges between the carboxyl groups of poly-a(2-8)NeuNAc and
the phosphates of the denatured DNA or poly(A) and poly(I)" (1).
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that IgM"°" is anti-NCAM (neural cell adhesion molecule) and does not react with any other CAMS
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The combining sites of mAbs to a(1-6)dextran have been classified into cavity-
type sites (7), also termed end binders (8), in which the terminal nonreducing one
or two sugars contribute most of the binding energy with additional binding energy
indicating a site size for W3129 complementary to five a(1-6)linked glucoses, and
groove-type sitesin which the combining site is complementary to an internal linear
sequence of up to six or seven sugars not involving the nonreducing end (7, 9); other
antibodies behave similarly with site sizes complementary to 4 to 7 sugars (9-11).
Poly-a(2-8)NeuNAc carbohydrate antigens and their antibodies behaved differ-
ently. Lindon et al. (12) noted by 3H-nuclear magnetic resonance (NMR) spec-
troscopy that group B polysaccharide tumbles as a rigid species with internal rota-
tion only at C9 of its side chains whereas the group C polysaccharide shows internal
or segmental motion in the C7 to C9 side chains of the sialic acids. Jennings et al
(13) found that, with horse anti-group B meningococcal serum, H46, higher molec-
ular weight oligosaccharides, e.g., a decasaccharide were required to inhibit binding to
intact group B polysaccharide, and Finne and Makela (14) also found a decasaccha-
ride was needed for direct binding. This was ascribed to the internal sugars of the
group B epitope being in an unusual conformation. Subsequent NMR studies by
Michon et al. (15) on a(2-8)-linked NeuNAc oligosaccharides of increasing sizes
established that an a(2-8)-linked pentamer is required before a linkage similar to
the internal linkages of colominic acid is generated.
The horse antiserum did not react with poly(A), poly(I), native, or denatured DNA,
but crossreacted weakly with poly(G) (1). Monoclonal IgM"°" and polyclonal H46
were approximately of equal potency in protecting infant rats against challenge with
virulent E. coli (1). A mouse IgG2a mAb, mAb735, to the group B polysaccharide
also did not crossreact with polynucleotides and denatured DNA (16). Another mono-
clonal anti-meningococcal group B recognized the embryonic neural cell adhesion
molecule (NCAM) but not the adult form (17) . Several other mouse mAbs to the
group B polysaccharide have been reported, but reactivity with polynucleotides and
DNA has not yet been studied (18).
The present study attempts to define the size, shape, and conformation of the
epitope of poly-a(2-8)NeuNAc most complementary to IgM"°" to account for the
crossreactivity with poly(A), poly(I), and denatured DNA and the differences in the
epitopes reacting with IgM"°" and H46.
Materials and Methods
Materials.
￿
The high molecular weight group B meningococcal polysaccharide prepara-
tions (GBMP) (1) were gifts ofDrs. John Robbins ofthe National Institutesof Health, Bethesda,
MD; Carlos Moreno then at Wellcome Research Laboratories, Beckenham, UK (3); and
Dr. E. C. Gotschlich ofThe Rockefeller University, New York, NY (lot XIX; reference 19).
Colominic acid (E. coli) and BSA were obtained from Sigma Chemical Co., St. Louis, MO.
Preparation of the N-propionylated (N-Pr)-GBMP (20) and the covalent linking of GBMP
to BSA were carried out as previously described (21). The a(2-'8)-homosioalooligosaccharides,
a(2-8)NeuNAc) were obtained by separation on an ion-exchange column of a partial
hydrolysate of colominic acid (13) and the equivalent N-propionylated oligosaccharides
(a(2-8)NeuNPr) were obtained using the same procedures. All a(2-8)-poly- and oligosac-
charides were used as the sodium salts. Poly(A) was obtained from Boehringer-Mannheim
Biochemicals, Indianapolis, IN.
A small molecular weight a(2-8)-linked sialic acid polymer was obtained by fractionation
of colominic acid on a Sephadex G100 column (1.6 x 90 cm.) (Pharmacia Fine Chemicals,KABAT ET AL.
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Piscataway, NJ) using PBS as eluant. A narrow fraction corresponding to Kd 0.35 in the elu-
tion profile was collected and desalted on a Sephadex G10 column (Pharmacia Fine Chem-
icals) using water as eluant, and was lyophilized. This fraction was shown to contain -20
a(2-8)-linked sialic acid residues, (NeuNAc)12o (22), which corresponds to an average mo-
lecular weight of6,000-7,000. Delipidated GBMP was obtained using two methods: (a) The
high molecular weight GBMP (10 mg) was treated with phospholipase A2 (EC 3.1.1.4) (2 .2
U) (Sigma Chemical Co.) according to published procedures of Gotschlich et al. (19). Part
of the solution was extracted with an equal volume of 80% phenol at room temperature to
remove the enzyme and the aqueous phase was lyophilized. That the product was completely
deaggregated was ascertained by the absence of a peak normally associated with the high
molecular weight GBMP in the void volume of its elution profile when eluted from a Sepharose
4B column (19, 22). A small aliquot of the original solution abovewas acidified and extracted
with chloroform, and the presence of lipids in the chloroform solution was determined by
GC-MS (19). A similar deaggregation ofthe high molecular weight GBMP was not observed
when it was treated with phospholipase C (EC 3 .1.4.3) (61 U) (Sigma Chemical Co.). (b) High
molecular weight GBMP (7.5 mg) was treated with 0.1 M NaOH (1 ml) for 16 h at 37°C.
The solution was neutralized with 0.2M HCI, dialyzed, and lyophilized to yield the delipi-
dated GBMP (7.2 mg). The product had a similar elution profile to that of the phospholipase
A2-treated GBMP when eluted from a Sepharose 4B column.
Radioactive Antigen-binding Assay.
￿
This assay was carried out by a modification of the Farr
technique (23) using an extrinsically 3H-labeled GBMP (13). The reaction mixture for the
radioactive antigen-binding assay consisted of mixing in Eppendorf polypropylene micro-
test tubes (Brinkmann Instruments Inc., Westbury, NJ) 50 pl of a solution containing 12.5
ng of 'H-labeled GBMP (100 cpm/ng), increasing amounts (0-100 ul) of antisera, and
sufficient PBS to take the total volume in the tubes to 150 pl. After incubation at 4°C for
16 h, 150 pl of saturated (at 4°C) ammonium sulfate or 150 g1 of 5% polyethylene glycol
(7,000) (Sigma Chemical Co.) in PBS at 4°C was added to the tubes and they were agitated
and left to stand at 4°C for 30 min. The tubes were centrifuged at 15,000 rpm for 10 min
and two aliquots of 130 gl were withdrawn from each tube. The aliquots were mixed with
5 ml of an aqueous scintillant containing xylene (Amersham Corp., Oakville, Ontario, Canada)
and the mixtures were counted in an LKB 1217 Rackbeta liquid scintillation counter.
Radioactive BindingInhibition Assay.
￿
Increasing concentrations of inhibitor in PBS (80 ul)
were added to 20 pl of a 1 :500 dilution of human IgM"°" sufficient to bind 50% of the 3H-
labeled GBMP in the absence of inhibitor. The samples were then processed as described
above in the radioactive antigen-binding assay using the 5% polyethylene glycol solution to
precipitate the antibody. The percent inhibition was calculated usingthe following formula:
percent inhibition = 100 x [(cpm with inhibitor - cpm without inhibitor)/(cpm without
antibody - cpm without inhibitor)] .
ELISAforBinding ofAntibody. The wells of Linbro EIA microtiter plates (Flow Laborato-
ries, Mississauga, Ontario, Canada) were coated by using a 10-11g/ml solution of the high
molecular weight GBMP in 0.05 M sodium carbonate-bicarbonate buffer at pH 9.6 (100
ul/well) at 37°C for 3 h or by using a 10 wg/ml solution of GBMP-BSA conjugate in PBS
(100 gl/well) for 3 h at room temperature. All plates were then kept for 16 h at 4°C. The
plates were blocked with 1% BSA in PBS for 10 min at room temperature. The wells were
then filled with 100 ul of serial 10-fold dilutions of antisera in BSA with 0 .02% Tween 20,
and the plates were left for 1 h at room temperature. After washing, 50 Rl of a 1 :200 dilution
in PBS of peroxidase-conjugated goat anti-human IgM or peroxidase-conjugated goat
anti-horse IgM (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) were added to
the wells and the plates were incubated for 1 h at room temperature.
2,2'-Azino-di-[3-ethylbenzthiazoline sulfonatel in cacodylate buffer with hydrogen peroxide
was used as the substrate and after 10 min the optical density at 414 nm was read using a
Titertek Multiscan M.C. (Flow Laboratories, Meckenheim, Federal Republic of Germany).
ELISAforInhibition ofAntibody Binding.
￿
A Corning 96-well round-bottomed platewas treated
with 100 ul of 0.1 M bicarbonate buffer pH 9.6 at room temperature (RT) for 1 h. The solu-
tion was removed and wells were washed three times with 0.05 % Tween 20 in PBS. The wells
were then coated with 100 P1 ofpoly-L-lysine (50 ug/ml, Sigma Chemical Co.) for 2 h at room702
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temperature. After washing with PBSTween, 100 gl of GBMP (3) (1 gg/well) or poly(A) (1
gg/well) were added to the wells, and the plates were left at RT for 1 h. The plates were washed,
blocked with 100 gl of poly-L-glutamate (50 ug/ml) at RT for 1 h, and again washed. 50 ttl
of inhibitor and 50 ltl of a 2 x 10-4 dilution in PBS of IgM"°" antiserum were added. The
contents of the wells were mixed by gentle tapping and the plate was placed at RT for 1 h
or at 4°C overnight. The wells were then washed thoroughly with PBSTween 20, and 100
gl ofa 1 :2,000 dilution in PBS of alkaline phosphatase-labeled goat anti-human IgM (Cappel
Laboratories, Malvern, PA) was added. The plate was again thoroughly washed, and 100
gl of 0.06% p-nitrophenylphosphate in diethanolamine buffer, pH 9.8, was added as sub-
strate. The reaction was stopped with 25 ltl 3N NaOH, and optical densities were read at
410 nm.
Results
IgM"°' and H46 were found to differ significantly in the Farr (23) RIA. H46 was
precipitated normally by ammonium sulfate but IgM"°" was not (data not shown).
Fig. 1 shows that substitution of polyethylene glycol in the RIA precipitated IgM"°"
but did not precipitate H46. Thus, polyethyleneglycol was used in RIA with Ig-
M"°" and ammonium sulfate for H46. The reason for this difference is not known.
Fig. 2 shows ELISA titrations of serial dilutions of IgM"°" and H46 against the
high molecular weight GBMP and against a mouse anti-CFA serum as a control.
The binding curves of IgM"°`' and H46 are identical.
Fig. 3 shows the results by RIA of assays using the (a(2-8)NeuNAc)" oligosac-
charides to inhibit the binding of [3H]GBMP to IgM"°". Fig. 4, A and B show the
results of ELISA assays using the (a(2-8)NeuNAc)n oligosaccharides to inhibit the
binding of IgM"°" to GBMP and to poly(A), respectively. The inhibition curves of
all three figures with the various oligosaccharides resemble each otherin that olig6sac-
charides larger than six or seven show strikingly increased inhibition. Similar findings
were obtained previously with H46 (13). This is unlike findings in other carbohy-
drate-anticarbohydrate systems (24) in which depending upon the system, the poly-
clonal or the monoclonal antibody, maximum inhibition has generally been found
with four to seven sugars, larger oligosaccharides having equivalent inhibitingpower
on a molar basis. It has been possible to estimate sizes of antibody combining sites
as that of the smallest oligosaccharide giving maximum inhibition.
For example, an IgM anti-a(1-6)dextran hybridoma,58.2C10.3 was inhibited
better by IM4 than by IM3 (isomaltotriose), which was better than IM2 (isomal-
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Radioactive antigen-binding assaystandard
curves 3H-labeled GBMP with horse 46 IgM (" ) and
human monoclonal IgM"°" (A) using polyethylene
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tose), butequimolarconcentrations of IM9, IM8, IM7, IM6, and IM5 all were iden-
tical, falling on the same line in inhibiting potency to the site filling IM4 (10). Simi-
larly, with the IgA anti-a(1-6)dextran hybridoma 37JE.5, IM9, IM8, and IM7 all
required 100 nmol for 50% inhibition of precipitation of the antibody by dextran,
whereas 190, 380, and 1,050 nmol of IM6, IM5, and IM4 were needed for 50%
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￿
ELISAtitrations of
IgM°'°" (A) and horse IgM
(") against thehigh molecular
weight GBMP. A mouse anti-
CFAserum(EI) wasused as the
controlserum. Curves represent
the mean titrations.
FIGURE 3.
￿
Inhibition of the binding of 3H-labeled
GBMP to human IgM"°" using a series of linear
a(2-8)-linked homosialooligosaccharides (a2-8
NeuNAc).704
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FIGURE 4. ELISA inhibitions by a(2-8)-linked
NeuNAc oligosaccharides of the binding of IgM"°`
antibody to GBMP (A) or to poly(A) (B).
inhibition. These findings are clearly unlike those obtained by RIA (Fig. 3) and
ELISA(Fig. 4, A and B) forinhibition with both the GBMP and poly(A). Compar-
ison ofFig. 4, A and B shows that the capacities ofthe (a(2-8)NeuNAc)n oligosac-
charides by ELISA to inhibit binding ofIgM"°" are remarkably similar, inhibition
being first seen over the range studied with a(2-8)-linked (NeuNAc)5; increasing
inhibition was seen as oligosaccharide size increased up to a(2-'8)-linked
(NeuNAc)12. It is especially interesting that the inhibiting potencies of a(2-'8)-
linked (NeuNAc) and (NeuNAc)9 fall on the same line whether the antibody of
IgM"°" was being displaced from GBMP or poly(A). This would suggest seven
a(2-8)-linked NeuNAc units as filling the site. The increased potency of the
(a(2-8)NeuNAc)iI and (a(2-8)NeuNAc)12 could be ascribable to these oligomers
being able to fit into a groove-type antibody combining site in several ways or, in
view of the NMR data, that the larger oligomers and GBMP exist in an unique
conformation (15). Especially significant in this connection may be the findings in
Fig. 4, A and B that the slopes of the inhibition lines of the oligomers competing
against GBMP are identical, whereas in thecompetitionwith poly(A), poly-a(2-'8)-
linked (NeuNAc)5 and (NeuNAc)6 have much lower slopes than the larger oligomers
that have about the same slopes. This increase in slope with poly-a(2-8)-linked
(NeuNAc)7, indicating increased effectiveness as an inhibitor, would be consistent
with it being the smallest oligomer that could exist in a site-filling conformation or
that had a sufficient number ofinternal residues in the preferred conformation re-
quired for reaction withthe group B antibody. In Fig. 3 theslopedifferencebetween
a(2-"8)-linked(NeuNAc)3 and (NeuNAc) is also striking and an increase in slope
is also seen between (NeuNAc)6 and (NeuNAc); why (NeuNAc)9 is more active in
RIA than (NeuNAc) whereas in ELISA it is identical is not clear, but conceivably100
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could bedueto some alteration in specificity ofthelabeled GBMP ora contribution
to binding from the solid-phase assay.
Fig. 5 shows that a(2-8)NeuNAc'zo and periodate oxidized a(2-8)NeuNAc2o
are much less active than the high molecular weight GBMP and a(2-8)NeuNActi2o-
BSA in inhibiting binding of 3H-labeled GBMP to human IgM"°°, indicating that
the multivalence of the oligomers of GBMP coupled to lipid in the intact GBMP
or the oligomers ofa(2-8)NeuNAc,2o coupled at the nonreducing ends to BSA pro-
duce equivalent increased bindingbased on sialic acid content. It may also be con-
cluded that the terminal nonreducing ends are not involved in the epitope.
Fig. 6 shows that the N-propionylated hexamer of a(2-8)-linked NeuNAc is
equivalent on a molar basis to the N-acetyl hexamer in inhibiting binding of 3H-
labeled GBMP to human IgM"°"; the N-propionyl dimer was some what less po-
tent than the N-acetyl dimer. The reactivity of the N-propionyl compounds may
indicate that the binding ofIgM"°° could be directed toward the acidic side ofthe
GBMP.
Fig. 7 shows ELISA titration of binding of IgM"°" and of H46 using
a(2-8)NeuNActi20-BSA and a(2-8)NeuNPr,2o-BSA as coating antigens. More
H46 antibody than IgM"°" is bound at the peak but the titers arecomparable. Again
N-acetyl and N-propionyl a(2-8)NeuNAc,2o-BSA give indistinguishable binding
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FIGURE 5.
￿
Inhibition of the binding
of [3H]-labeled GBMP to human
IgM"°° using (A) NeuNAc-2o' (p)
periodate oxidized NeuNAc-2o' (e)
high m.w. GBMP and (")
NeuNAc-2o-BSA conjugate.
FIGURE 6.
￿
Inhibition ofthebinding of [3H]-labeled
GBMP to human IgM"°" using linear a(2-8)-
linked N-acetylated (NeuNAc)n andtheequivalent
N-propionylated (NeuNPr)n oligosaccharides.poly-a(2-8)NeuNAc EPITOPE MOST COMPLIMENTARY to IgM"
FIGURE 7. ELISA titrations
of horse IgM using (") Neu-
NActi2o-BSA and (O) Neu-
Pro-2o-BSA as the coating an-
tigens and IgM"°" using (N)
NeuNActi20-BSA and(0) Neu-
NPr2o-BSA as the coating an-
tigens.
curves with IgM"°" as well as with H46, which are the same within experimental
error.
Fig. 8, A and B, provide comparisons ofthe behavior in quantitative precipitin
testsofvarious intact HGBMPsand theGotschlich sample lot XIX, after treatment
with phospholipase C, phospholipase A2, and dilute alkali, as well as after coupling
to BSA. With monoclonal IgM"°" (Fig. 8 A), phospholipase C-treated lot XIX,
which did not split offthelipid, shows verylittlechange in its quantitative precipitin
curve; it is slightly lessactive per unit weight and this couldbe dueto slight contami-
nation with inert materials in the phospholipase C which would reduce the amount
of polysaccharide in the weighed sample. The phospholipase A2- and the alkali-
treated samples showed somewhat reduced precipitatingactivity perunit weight but
were essentially identical. Both precipitated -90% ofthe maximum Nobtained with
lot XIX and the other GBMP . However, the amount of polysaccharide needed to
give 50% precipitation was 1.7 wg of the enzyme-treated samples as compared with
0.8 ggfor the original GBMPs. TheGBMP-BSA precipitated about the same amount
of N at the maximum, but -2.9 wg was needed for 50% precipitation.
With polyclonal H46, the phospholipase C-, phospholipase A2-, alkali-treated
lot XIX and GBMP-BSA precipitated a maximum of4.6, 3.7, 2.8, and 4.4 wg total
N as compared with 7.2 gg N foruntreated lot XIX, and considerably more ofeach
sample was required for precipitation. Nevertheless, both IgM"°" and H46 gave
good precipitin curves after these various treatments, showing that the individual
poly a(2-8)NeuNAc chains liberated enzymatically or by alkali are multivalent.
Why precipitation of these delipidated compounds with polyclonal H46 is less than
with monoclonal IgM"°" is not clear.s
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FIGURE 8.
￿
Comparison of in-
tact GBMP lot XIX (Gotsch-
lich) ("); (Moreno) (G);
GBMP-BSA (p); and phos-
pholipase A2 (SI) and alkali
(/) delipidated GBMP and
controlphospholipase C treated
GBMP(®). Nitrogen ofthean-
tigen has been subtracted in
each case. A IgM"°`'; B H46.
Discussion
The epitope of the group B meningococcal and of E, coli K1 polysaccharide is
unique among polysaccharide epitopes thus far reported. Other carbohydrate epi-
topes which may vary in size from a di- or trisaccharide to ahexa- or heptasaccha-
ride in site filling complementary area (24) and may be specific for the terminal
nonreducing end or forinternal segments ofthe polysaccharide (7). With the group
B meningococcal epitope, increased inhibition was obtained with oligosaccharides
ofchain length up to 16 U with H46 (13) and up to about 12 a(2-8)linked NeuNAc
residues, the longest tested with IgM"°" (Figs. 3 and 4). Moreover, monoclonal
IgM"°" crossreacts extensively with poly(A), poly(I), and with denatured DNA
whereas neither the horse polyclonal antibody, H46 (1), nor a mouse monoclonal
anti-poly a(2-8)NeuNAc (16) show such crossreactivity. It is important that the in-
hibition of precipitation by various oligosaccharides of IgM"°° by GBMP and by
poly(A) showed only minor differences as discussedabove (Fig. 4, A and B). By elec-
trophoresis of IgM"°", the monoclonal spike was removed completely by group B
polysaccharide and poly(A). Since they are both binding to the same sites on
IgM"°°, the data lend support to the hypothesis (1) that negative charges with ap-
propriate spacing is what is being recognized (see reference 6).
The uniqueness of the epitope is strongly supported by '3C-NMR spectra (15),
which clearly established that in oligosaccharide (a(2-8)NeuNAc)lo only the inner
six residues assume a conformation that is representative of the epitope of GBMP
This number of residues is consistent with the size range of the usual carbohydrate
epitopes (7, 9, 10, 24). The existence of such conformationally controlled epitopes
(13, 25) adds another dimension to the already protean specificity of the immune
system and many other instances may be found.
Gotschlich et al. (19) found that the group B polysaccharide is built of multiple
chains of poly-a(2-8)NeuNAc connected by lipid; this would provide multiple epi-
topes specific for the non-reducing end in addition to the internal epitopes, sug-
gesting the possibility (13, 14) that the difference between the combining sites of
IgM"°" and H46 might be related to this difference. Our data rule out this expla-
nation because the single chains liberated by enzyme or alkaline hydrolysis retain
their precipitating power with both IgM"°" and H46 (Fig. 8). In addition, substi-708
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tution of BSAat thenonreducing ends of GBMP does not affect thecapacity of both
to precipitate or to bind in ELISA based on equivalent sialic acid content (Fig. 7),
and selective periodate oxidation of the terminal nonreducing residue does not affect
binding. Thus, the differences between the combining sites of IgM"°" and H46 must
be accounted for with both kinds of sites being complementary to oligomeric pat-
terns of internal segments of a(2-8)linked NeuNAc notinvolvingthe terminal non-
reducing end. The most important test of such a hypothesis would be its ability to
account for the reactivity of IgM"°° to react with poly(A), poly (I), and denatured
DNA, whereas H46 (1) and the mouse monoclonal (16) do not.
It has been demonstrated (15) that in the conformationally controlled epitope of
the GBMP or of the poly-a(2-8)NeuNAc)N2o, the carboxylate and acetamido
groups are lined up on opposite sides of the molecule. One might hypothesize that
the groove-type IgM"°" binds to an epitope located on the carboxylate side of the
molecule. It is of interest that Zopf et al. (26) have shown that some antibodies can
be directed toward one side of a tetrasaccharide while others can be specific for the
opposite side, each ofentirely different specificity. Consistent with this is the finding
(Fig. 6) that the N-acetamido and the N-propionyl hexamers react equallywell with
IgM"°", although the N-acetamido dimer is somewhat better than the N-propionyl
dimer. The latter compounds might be too small to react typically in a large site.
If the epitope involved their direct contact in the groove, the N-propionylated com-
pounds mightbe expected to react relatively poorly compared with theN-acetamido
compounds. This would suggest that the original hypothesis (1) that a similardistri-
bution of negative charges on the GBMP and the poly(A), poly(I), and denatured
DNA is the basis of the crossreactivity is correct. Single-stranded poly(A), poly(I);
and denatured DNA with all the phosphate groups on one side of the molecule and
all the bases on theother existand would mimicthe basic structure of the conforma-
tionally controlled innerresidues of theGBMP. In addition, these molecules exhibit
secondary structure; poly(A) in its unprotonated form has helical and coiled do-
mains (27) . It would be of interest to determine which of these conformations con-
tains the epitope that binds to IgM"°", since if it were the former it would provide
evidence that the conformationally controlled epitope of GBMP is also helical in
structure. A structure consisting of two parallel intertwined helical chains has also
been proposed (28) forpoly(A) fibers. At present it is not possible to account defini-
tively for the ability of IgM"°" to react with poly(A), poly(I), and denatured DNA,
whereas H46 does not. Since both are conformationally controlled, IgM"°" must
be recognizing some oligomeric structures common to GBMP and the polynucleo-
tides, whereas H46is recognizing a pattern not shared by GBMP and poly(A), poly
(I), poly(G), and denatured DNA. The data in Figs . 7 and 8 indicate that both are
reacting with the acidic side of the molecule. It is possible that the distribution of
negatively charged and protonated carboxyls and phosphates under the pH condi-
tions used in Figs. 7 and 8 is such as to determine this. Such an instance was found
in which two human monoclonals IgM"y and IgM1E^ both most specific for Kleb-
siella K30 with terminal nonreducing 3,4-pyruvylated DGa1-linked a showed a
striking difference in ability to crossreact with K21 with terminal nonreducing 4,6-
pyruvylated DGal-linked R (29). K30 and K21 gave identical precipitin curves with
IgM"^" from pH 4-7 and IgMIE^ with K30, whereas with K21 no precipitation was
obtained from pH 5.3-7 but at pH 4, K21 precipitated identically to K30(30). Thesefindings suggest that a study of the precipitin curves of IgM"°" and H46 at different
pH with GBMP and with poly(A) might clarify the basis for this crossreactivity.
Summary
The fine structure of the combining site of human mAb IgM"°" to poly_
a(2-8)linked NeuNAc, the epitope of the group B meningococcal and E. coli Kl
polysaccharides, has been probed using RIA and ELISA. Inhibition by oligomers
ranging from 2 to 12 residues was used to assay binding to IgM"°" by group B
meningococcal polysaccharide preparations (GBMP) or by poly(A). The inhibitory
properties of the oligomers were almost identical in both assays of the binding of
GBMP to horse IgM (H46). This evidence and the finding that both GBMP and
poly(A) precipitated IgM"°" equally per unit weight indicated that the epitope of
poly(A) must mimic an equivalent epitope on GBMP despite the absence of any
apparent common structural features in the two molecules. Unlike most carbohy-
drate-anticarbohydrate systems in which the site is saturated by oligomers of up to
six or seven sugars, all the anti-a(2-8)NeuNAc systems above required much larger
oligomers. Because these oligomers are larger than the maximum size of an anti-
body site the epitope must be conformationally controlled, and this has been confirmed
by nuclear magnetic resonance spectroscopy.
However, despite the above similarities, GBMP and poly(A) were differentiated
in that only GBMP bound to H46. Smaller linear molecules obtained by delipidating
the GBMP, as well as periodate-oxidized GBMP with its nonreducing end oxidized
or linked covalently to BSA, bound to and precipitated IgM"' and H46. This
showed that, despite their differences, terminal nonreducing ends were not involved
and that both epitopes were located in the conformationally controlledinner residues
of the GBMP. The difference thus must reside in the ability of IgM"' and H46
to recognize different structural aspects ofthe same conformationally controlled inner
residues. The ELISA data indicate that both IgM"' and H46 have groove-type sites
that bind exclusively to an epitope located on the acidic side of the inner residues.
The differences determining the ability of IgM"' and the failure of H46 to cross-
react with poly(A), poly(I), and denatured DNA, may depend on differences in the
degree of protonation required by each antibody, and this may be clarified by a study
of the effects of pH on the precipitin behavior of IgM"' and H46.
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